| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 192.88 | 3.3% | 30.7% |
| Total Income | 192.88 | 3.3% | 30.7% |
| Expenditure | 201.31 | 2.0% | 1.8% |
| PBT | -5.19 | 64.0% | 88.7% |
| Net Profit | -5.21 | 63.4% | 88.7% |
| OPM | -4.37% | 5.65pp | 29.73pp |
| NPM | -2.70% | 4.91pp | 28.60pp |
| EPS | -0.16 | 63.6% | 89.2% |
iRhythm Technologies Reports Q3 2025 Revenue Up 30.7% YoY
04 May 2026 · 4 May, 8:27 am
Summary
iRhythm Technologies announced its financial results for the third quarter ended September 30, 2025. Revenue for the quarter was $192.9 million, a 30.7% increase compared to the same period in 2024. Gross margin improved to 71.1%, a 230-basis point increase year-over-year. The company's unrestricted cash, cash equivalents, and marketable securities amounted to $565.2 million as of September 30, 2025. iRhythm has increased its fiscal year 2025 guidance for revenue and adjusted EBITDA margin.
Key Highlights
- 1
iRhythm Technologies reported revenue of $192.9 million for the third quarter of 2025, a 30.7% increase compared to the third quarter of 2024.
- 2
The company's gross margin for the third quarter of 2025 was 71.1%, a 230-basis point increase compared to the third quarter of 2024.
- 3
iRhythm's unrestricted cash, cash equivalents, and marketable securities totaled $565.2 million as of September 30, 2025.
- 4
The company increased its fiscal year 2025 guidance for revenue and adjusted EBITDA margin.
- 5
Third quarter 2025 saw record quarterly revenue driven by momentum in core long-term continuous monitoring business and sustained demand for Zio AT.
- 6
Net loss for the third quarter of 2025 was $5.2 million, or a diluted loss of $0.16 per share, compared with net loss of $46.2 million, or a diluted loss of $1.48 per share, for the same period in 2024.
Management Comments
Quentin Blackford
"iRhythm delivered another quarter of strong performance, reflecting the scalability of our platform and the growing adoption of our differentiated technology across the healthcare ecosystem," said Quentin Blackford, President and Chief Executive Officer of iRhythm. "With third quarter of 2025 revenue up 30.7% year-over-year, we continue to demonstrate consistent execution and durable demand across core accounts as well as continued growth into emerging innovative channel partnerships. Our ongoing expansion into primary care and population health programs, combined with meaningful progress in EHR integration and new clinical evidence, reinforces our leadership in proactive cardiac monitoring. We are advancing our innovation pipeline — including submission of our next-generation Zio MCT solution to the FDA and early work in sleep diagnostics — while driving operational efficiency and profitable growth. Importantly, we achieved record free cash flow generation during the quarter and anticipate this year to be free cash flow positive on an annual basis for the first time in company history. iRhythm’s mission remains clear: to transform cardiac care through actionable insights, empowering clinicians and improving outcomes for millions of patients worldwide."
Informational and educational content only. Not investment advice.